WAYNE, PA — Aclaris Therapeutics, Inc., a Pennsylvania-based biopharmaceutical company, announced this week that it has entered into an exclusive patent license agreement with Sun Pharmaceutical Industries, Inc. (Sun Pharma). This agreement allows Sun Pharma to utilize certain patents held by Aclaris for the use of deuruxolitinib, a JAK inhibitor developed by Sun Pharma, or other isotopic forms of ruxolitinib, to treat alopecia areata (AA) and androgenetic alopecia (AGA).
The licensing agreement includes an upfront payment of $15 million from Sun Pharma to Aclaris, with additional payments contingent on regulatory and commercial milestones. In addition, Sun Pharma will pay royalties to Aclaris on net sales. Aclaris, in turn, is obligated to share a portion of the consideration received from Sun Pharma under separate contractual obligations with a third party from whom Aclaris exclusively licenses the patents.
James Loerop, Chief Business Officer of Aclaris, expressed his satisfaction with the new partnership, stating, “We are pleased to announce this patent license agreement with Sun Pharma, which represents our second out-license for this patent portfolio.”
The agreement underscores the increasing interest and investment in treatments for AA and AGA, conditions that affect millions of people worldwide. As such, the development and commercialization of deuruxolitinib could potentially represent a significant advancement in the treatment of these prevalent hair loss conditions.
The deal also highlights the strategic business approach of both Aclaris and Sun Pharma, as they continue to identify and pursue opportunities for growth and expansion within the pharmaceutical industry. With this partnership, both companies demonstrate their commitment to improving patient outcomes through innovative treatments and therapies.
This agreement follows a series of successful collaborations between Aclaris and Sun Pharma, cementing a fruitful relationship that continues to contribute significantly to the pharmaceutical landscape. The partnership not only leverages the unique strengths of each company but also paves the way for future innovations in the field of dermatology and beyond.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and Microsoft Start.